ENTRY       D05380                      Drug
NAME        Pazopanib hydrochloride (JAN/USAN);
            Votrient (TN)
PRODUCT     VOTRIENT (Novartis Pharmaceuticals Corporation)
FORMULA     C21H23N7O2S. HCl
EXACT_MASS  473.1401
MOL_WEIGHT  473.979
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01EX03
            Product: D05380<JP/US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor
  DISEASE   Renal cell carcinoma [DS:H00021]
            Soft tissue sarcoma [DS:H02427]
TARGET      PDGFR [HSA:5156 5159] [KO:K04363 K05089]
            VEGFR1 (FLT1) [HSA:2321] [KO:K05096]
            VEGFR2 (KDR) [HSA:3791] [KO:K05098]
            VEGFR3 (FLT4) [HSA:2324] [KO:K05097]
            KIT (CD117) [HSA:3815] [KO:K05091]
  PATHWAY   hsa04010(2321+2324+3791+3815+5156+5159)  MAPK signaling pathway
            hsa05200(2324+3815+5156+5159)  Pathways in cancer
INTERACTION  
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EX Other protein kinase inhibitors
                 L01EX03 Pazopanib
                  D05380  Pazopanib hydrochloride (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Pazopanib
                D05380  Pazopanib hydrochloride (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D05380  Pazopanib hydrochloride (JAN/USAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                D05380  Pazopanib hydrochloride
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               PDGFR family
                PDGFR
                 D05380  Pazopanib hydrochloride (JAN/USAN) &lt;JP/US&gt;
                KIT (CD117)
                 D05380  Pazopanib hydrochloride (JAN/USAN) &lt;JP/US&gt;
               VEGFR family
                VEGFR1 (FLT1)
                 D05380  Pazopanib hydrochloride (JAN/USAN) &lt;JP/US&gt;
                VEGFR2 (KDR)
                 D05380  Pazopanib hydrochloride (JAN/USAN) &lt;JP/US&gt;
                VEGFR3 (FLT4)
                 D05380  Pazopanib hydrochloride (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D05380
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D05380
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D05380
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D05380
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D05380
DBLINKS     CAS: 635702-64-6
            PubChem: 47207056
            ChEBI: 71217
            LigandBox: D05380
ATOM        32
            1   C8x C     8.1900  -18.2000
            2   C8y C     8.1900  -19.6000
            3   C8y C     9.4024  -20.3000
            4   C8x C    10.6149  -19.6000
            5   C8y C    10.6149  -18.2000
            6   C8x C     9.4024  -17.5000
            7   N5x N    13.0397  -19.6000
            8   C8y C    13.0397  -18.2000
            9   N1b N    11.8273  -17.5000
            10  C8x C    14.2522  -20.3000
            11  C8x C    15.4646  -19.6000
            12  C8y C    15.4646  -18.2000
            13  N5x N    14.2522  -17.5000
            14  N1c N    16.6811  -17.4977
            15  C8y C    17.8786  -18.1892
            16  C1a C    16.6811  -16.1002
            17  C1a C     6.9776  -20.3000
            18  S4a S     9.4024  -21.6998
            19  N1a N     9.4024  -23.0998
            20  O3c O     7.9800  -21.6998
            21  O3c O    10.7800  -21.6998
            22  C8x C    17.8787  -19.5997
            23  C8x C    19.0911  -20.2996
            24  C8y C    20.3035  -19.5996
            25  C8y C    20.3035  -18.1891
            26  C8x C    19.0910  -17.4892
            27  C8y C    21.6450  -20.0354
            28  N4y N    22.4741  -18.8942
            29  N5x N    21.6449  -17.7532
            30  C1a C    23.8700  -18.8942
            31  C1a C    22.0716  -21.3485
            32  X   Cl   22.1900  -23.9400
BOND        34
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     7   8 1
            8     8   9 1
            9     5   9 1
            10    7  10 2
            11   10  11 1
            12   11  12 2
            13   12  13 1
            14    8  13 2
            15   12  14 1
            16   14  15 1
            17   14  16 1
            18    2  17 1
            19    3  18 1
            20   18  19 1
            21   18  20 2
            22   18  21 2
            23   15  22 1
            24   22  23 2
            25   23  24 1
            26   24  25 1
            27   25  26 1
            28   15  26 2
            29   24  27 2
            30   27  28 1
            31   28  29 1
            32   25  29 2
            33   28  30 1
            34   27  31 1
///
